Laporan Laba Rugi (TTM)
Laporan Laba Rugi Mereo BioPharma Group plc - Depositary Receipt (Common Stock) menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18 | 36 | 36 | 36 | 18 | 0 | 0 | 9 | 9 | 10 | 10 | 1 | 1 | 0 |
| Change (%) | 100.00 | 0.00 | 0.00 | -50.00 | -100.00 | NaN | ∞ | 0.00 | 11.11 | 0.00 | -90.00 | 0.00 | -50.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | ||
| Cost Of Sales | 9 | 18 | 18 | 18 | 9 | -1 | -1 | 2 | 2 | 3 | 3 | -1 | -0 | 0 |
| Change (%) | 100.00 | -0.63 | -0.64 | -51.62 | -106.71 | 54.34 | -365.90 | 3.60 | 4.21 | 13.48 | -117.43 | -46.37 | -148.35 | |
| % of Revenue | 49.74 | 49.74 | 49.43 | 49.11 | 47.52 | 26.49 | 27.45 | 25.74 | 29.21 | -50.90 | -27.30 | 26.40 | ||
| Gross Operating Profit | 9 | 18 | 18 | 19 | 10 | 1 | 1 | 7 | 7 | 7 | 7 | 2 | 1 | 0 |
| Change (%) | 100.00 | 0.62 | 0.62 | -48.43 | -93.93 | 54.34 | 637.78 | -1.30 | 13.72 | -4.67 | -78.68 | -15.64 | -71.09 | |
| % of Revenue | 50.26 | 50.26 | 50.57 | 50.89 | 52.48 | 73.51 | 72.55 | 74.26 | 70.79 | 150.90 | 127.30 | 73.60 | ||
| SG&A | 21 | 22 | 19 | 16 | 16 | 16 | 22 | 24 | 23 | 18 | 18 | 23 | 24 | 25 |
| Change (%) | 1.07 | -13.26 | -15.29 | 0.52 | 0.52 | 36.79 | 8.94 | -4.32 | -19.74 | -2.95 | 29.09 | 2.14 | 7.83 | |
| % of Revenue | 117.66 | 59.46 | 51.58 | 43.70 | 87.85 | 266.58 | 255.06 | 184.24 | 178.80 | 2,308.20 | 2,357.70 | 5,084.60 | ||
| R&D | 17 | 18 | 21 | 24 | 25 | 27 | 29 | 19 | 18 | 16 | 15 | 16 | 16 | 20 |
| Change (%) | 4.05 | 16.45 | 14.13 | 7.35 | 6.85 | 7.04 | -35.33 | -4.53 | -9.63 | -8.00 | 10.00 | -3.48 | 24.11 | |
| % of Revenue | 93.44 | 48.61 | 56.61 | 64.61 | 138.72 | 207.85 | 198.42 | 161.38 | 148.47 | 1,633.10 | 1,576.20 | 3,912.40 | ||
| OpEx | 48 | 58 | 57 | 57 | 50 | 43 | 50 | 45 | 43 | 37 | 36 | 39 | 39 | 45 |
| Change (%) | 21.00 | -0.13 | -0.13 | -12.94 | -14.87 | 17.65 | -9.93 | -3.99 | -14.20 | -4.01 | 9.13 | 0.42 | 15.49 | |
| % of Revenue | 260.85 | 157.82 | 157.62 | 157.42 | 274.08 | 500.92 | 480.93 | 371.36 | 356.48 | 3,890.40 | 3,906.60 | 9,023.40 | ||
| Operating Income | -29 | -21 | -21 | -21 | -32 | -43 | -50 | -36 | -34 | -27 | -26 | -38 | -38 | -45 |
| Change (%) | -28.11 | -0.35 | -0.35 | 51.60 | 34.04 | 17.65 | -27.91 | -4.99 | -20.85 | -5.48 | 47.79 | 0.43 | 17.21 | |
| % of Revenue | -160.85 | -57.82 | -57.62 | -57.42 | -174.08 | -400.92 | -380.93 | -271.36 | -256.48 | -3,790.40 | -3,806.60 | -8,923.40 | ||
| Interest Expense | -6 | -5 | -5 | -4 | -4 | -4 | -4 | -4 | -4 | -3 | -2 | -2 | -1 | -1 |
| Change (%) | -7.59 | -14.67 | -17.17 | -2.87 | -2.96 | 14.37 | -4.95 | -4.90 | -21.70 | -17.01 | -29.19 | -20.38 | -30.79 | |
| % of Revenue | -31.71 | -14.65 | -12.50 | -10.36 | -20.12 | -42.99 | -40.88 | -28.81 | -23.91 | -169.30 | -134.80 | -186.60 | ||
| Net Income | -95 | -27 | -7 | 13 | -3 | -19 | -31 | -32 | -31 | -29 | -26 | -37 | -45 | -50 |
| Change (%) | -71.74 | -73.63 | -279.28 | -122.77 | 539.10 | 69.69 | 0.87 | -2.86 | -4.31 | -10.61 | 39.88 | 22.98 | 9.34 | |
| % of Revenue | -522.57 | -73.83 | -19.47 | 34.90 | -15.90 | -352.24 | -342.15 | -294.66 | -263.41 | -3,684.70 | -4,531.60 | -9,909.60 | ||
Source: Capital IQ
